CARsgen Therapeutics

May 11, 2025

CARsgen Announces Preliminary Clinical Data for Allogeneic BCMA CAR-T CT0596, Demonstrating Favorable Safety and Efficacy

Mar 18, 2025

CARsgen Announced 2024 Annual Results

Jan 20, 2025

CARsgen's Allogeneic CD38 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial

Dec 30, 2024

CARsgen Announces Positive Topline Results from China GC/GEJ Pivotal Phase II Clinical Trial of Claudin18.2 CAR-T (Satri-cel)

Nov 06, 2024

CARsgen® to Present Zevor-cel, CT071 and CT0590 at ASH 2024 Annual Congress

Oct 31, 2024

CARsgen® U.S. Clinical Holds Lifted by FDA

Aug 29, 2024

CARsgen® Announces 2024 Interim Results

Jun 15, 2024

CARsgen Presents First-in-human Results of GPRC5D Targeting CAR-T CT071 at EHA 2024

Jun 04, 2024

CARsgen Presents Updated Results on Satri-cel in Nature Medicine and at 2024 ASCO

Apr 29, 2024

CARsgen Submitted Responses to FDA Observations

Mar 27, 2024

CARsgen Announced 2023 Annual Results

Mar 01, 2024

NMPA Approves the NDA for CARsgen's BCMA CAR-T Therapy Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma

Jan 19, 2024

CARsgen's Presents Updated Research Results on CT041 at 2024 ASCO GI Meeting

Jan 15, 2024

CARsgen's CT011 achieves IND clearance from the NMPA for the GPC3-positive stage a hepatocellular carcinoma at high risk of recurrence after surgical resection